直覺手術 (ISRG) 2015 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Welcome to the Intuitive Surgical Q4 2015 earnings release conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time.

    歡迎參加直覺外科(Intuitive Surgical)2015 年第四季財報發布電話會議。此刻,所有與會者皆處於僅收聽模式。稍後我們將進行問答環節,屆時將提供相關指示。

  • (Operator Instructions)

    (接線員指示)

  • As a reminder, today's conference is being recorded and now I would like to turn the conference over to the Senior Director of Finance for Investor Relations for Intuitive Surgical, Mr. Calvin Darling. Please go ahead, sir.

    提醒各位,今天的會議將被錄音。現在我想將會議交給直覺外科投資人關係部門的財務資深總監 Calvin Darling 先生。先生,請開始。

  • Calvin Darling - Senior Director of Finance and IR

    Calvin Darling - Senior Director of Finance and IR

  • Thank you. Good afternoon and welcome to Intuitive Surgical's fourth quarter earnings conference call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Senior Director of Finance.

    謝謝。各位下午好,歡迎參加直覺外科第四季財報電話會議。今天與我一同出席的有:總裁暨執行長 Gary Guthart;財務長 Marshall Mohr;以及財務資深總監 Patrick Clingan。

  • Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the Company's Securities and Exchange Commission filings, including our most recent Form 10-K filed on February 5, 2015 and 10-Q filed on October 21, 2015. These filings can be found through our website or at the SEC's EDGAR database. Prospective investors are cautioned not to place undue reliance on such forward-looking statements.

    在開始之前,我想提醒各位,今天電話會議中的評論可能被視為包含前瞻性陳述。由於某些風險與不確定性,實際結果可能與明示或暗示的內容有重大差異。這些風險與不確定性已在本公司向美國證券交易委員會(SEC)提交的文件中詳細說明,包括我們最近於 2015 年 2 月 5 日提交的 Form 10-K,以及於 2015 年 10 月 21 日提交的 10-Q。這些文件可透過我們的網站或 SEC 的 EDGAR 資料庫查閱。提醒潛在投資人勿過度依賴此類前瞻性陳述。

  • Please note that this conference call will be available for audio replay on our website at Intuitivesurgical.com, on the Audio Archive section under our Investor Relations page. In addition, today's press release and supplementary financial data tables have been posted to our website.

    請注意,本次電話會議的音訊重播將可在我們網站 Intuitivesurgical.com 的投資人關係頁面下之「音訊存檔」區收聽。此外,今天的新聞稿與補充財務資料表亦已發布於我們的網站。

  • Today's format will consist of providing you with our highlights from our fourth quarter results, as described in our press release announced earlier today, followed by a question-and-answer session. Gary will present the quarter's business and operational highlights, Marshall will provide a review of fourth quarter financial results, Patrick will discuss marketing and clinical highlights, and I will provide our financial outlook for 2016 and finally, we will host a question-and-answer session. With that, I will turn it over to Gary.

    今天的流程將先為各位說明我們第四季業績重點(如今日稍早發布的新聞稿所述),接著進行問答環節。Gary 將介紹本季的業務與營運重點;Marshall 將回顧第四季財務結果;Patrick 將說明行銷與臨床重點;我將提供 2016 年財務展望;最後我們將進行問答環節。接下來我把時間交給 Gary。

  • Gary Guthart - President & CEO

    Gary Guthart - President & CEO

  • Good afternoon and thank you for joining us on the call today. 2015 was a good year for Intuitive with increased use of our products around the globe and solid operational execution. Our focus in 2015 was to drive adoption of our platform in general surgery, expand our da Vinci Xi Surgical System product line, increase our organizational capability and performance in international markets, and improve contribution margins for our newly launched products.

    各位下午好,感謝今天加入我們的電話會議。2015 年對直覺外科而言是表現良好的一年,我們的產品在全球使用量增加,且營運執行穩健。我們在 2015 年的重點是:推動我們平台在一般外科的採用、擴展達文西 Xi 手術系統(da Vinci Xi Surgical System)產品線、提升我們在國際市場的組織能力與績效,以及改善新上市產品的貢獻毛利。

  • Themes that emerged at the close of 2014 continued into 2015, with strong performance in general surgery and international procedure growth. Full-year global procedure growth was approximately 14%, led by growth in general surgery, growth in the use of da Vinci Surgical Systems outside the United States, and strength in urology.

    2014 年底浮現的主題延續至 2015 年,一般外科表現強勁且國際手術量成長。全年全球手術量成長約 14%,主要由一般外科成長、達文西手術系統在美國以外地區使用量增加,以及泌尿科的強勁表現所帶動。

  • US general surgery growth was approximately 31% for the year, made up of strong growth in inguinal hernia repair, ventral hernia repair and colorectal surgery. Use of single-site in cholecystectomy and hysterectomy declined for the year. Outside of the United States, procedure growth was strong, rising approximately 26% over procedures in 2014. Patrick will review procedure trends in greater detail later in the call.

    美國一般外科全年成長約 31%,主要來自腹股溝疝氣修補、腹壁疝氣修補與大腸直腸手術的強勁成長。全年在膽囊切除術與子宮切除術中使用單孔(single-site)的比重則下降。在美國以外地區,手術量成長強勁,較 2014 年手術量增加約 26%。Patrick 稍後將在電話會議中更詳細回顧手術量趨勢。

  • Looking at trends in capital sales for the year, capital placements increased in 2015 to 492 from 431 placements in 2014. Customer interest and acceptance of our latest Platform, da Vinci Xi, has been positive, with Xi making up the majority of placements for the year. In 2015, we shipped 298 systems in the United States, 90 in Europe, 77 in Asia, and 27 in other global markets.

    就全年資本設備銷售趨勢而言,2015 年資本設備裝機(capital placements)增至 492 台,高於 2014 年的 431 台。客戶對我們最新平台達文西 Xi 的興趣與接受度表現正面,Xi 佔全年裝機的大多數。2015 年,我們在美國出貨 298 套系統、歐洲 90 套、亞洲 77 套,以及其他全球市場 27 套。

  • Our operations teams remain focused on optimizing our manufacturing, design and supply chains for our newer products. Progress in the back half of 2015 has been solid, with steady improvements in reducing product costs for our new systems and advanced instruments. We expect our product cost to continue to improve in 2016 and 2017 as a result of these efforts. As we have said before, our offerings make up an ecosystem designed to encompass our customers' needs in building and running outstanding robotic surgery programs.

    我們的營運團隊仍專注於為較新的產品優化製造、設計與供應鏈。2015 年下半年進展穩健,持續改善並降低新系統與先進器械的產品成本。我們預期在這些努力下,產品成本將於 2016 年與 2017 年持續改善。如同我們先前所說,我們的產品與服務構成一個生態系,旨在涵蓋客戶在建立與營運卓越機器人手術計畫時的需求。

  • 2015 was the year in which we focused on enabling our ecosystem with new product launches globally. We launched our da Vinci Xi system with a core set of instruments, Vessel Sealer and Firefly Fluorescence Imaging in 2014. We broadened our access to our Xi System with international regulatory clearances through the year. We also added our 45-millimeter Xi stapler in Q1 as well as Harmonic Curved Shears and a second set of instruments in Q2 of 2015. We submitted our 510(k)s for our 30-millimeter stapler for Xi, single-site instrument kit for Xi as well as other Xi accessories in the second half of 2015. I am pleased to report that we obtained FDA clearance for Integrated Xi Table Motion this month.

    2015 年是我們聚焦於透過全球新產品上市來強化生態系的一年。我們於 2014 年推出達文西 Xi 系統,搭配一套核心器械、血管封合器(Vessel Sealer)以及 Firefly 螢光影像(Fluorescence Imaging)。我們在全年透過取得各國法規核准,擴大 Xi 系統在國際市場的可及性。我們也在 2015 年第一季新增 45 毫米 Xi 吻合器,並於第二季新增 Harmonic Curved Shears 以及第二套器械。我們在 2015 年下半年提交了 Xi 用 30 毫米吻合器、Xi 用單孔器械套件,以及其他 Xi 配件的 510(k) 申請。我很高興報告,我們本月已取得 FDA 對整合式 Xi 手術台移動(Integrated Xi Table Motion)的核准。

  • In addition to products, our surgeon customers can choose from dozens of training courses provided by academic surgeons as well as courses designed for assistants and other operating room staff. Our customers own over 1,400 surgical simulators and over 600 dual consoles to assist them in technology training. In addition our teams have provided detailed analytic and operational support for customers seeking to optimize and benchmark their programs relative to international norms. We believe the combination of these products and services are important to fully enable our customers.

    除了產品之外,我們的外科醫師客戶也可選擇數十種訓練課程,包含由學術外科醫師提供的課程,以及為助手與其他手術室人員設計的課程。我們的客戶擁有超過 1,400 台手術模擬器與超過 600 套雙控制台,以協助其進行技術訓練。此外,對於希望依國際常模優化並對標其計畫的客戶,我們的團隊也提供詳細的分析與營運支援。我們相信,這些產品與服務的組合對於全面賦能我們的客戶至關重要。

  • Looking back at the full year of 2015, our operating performance is summarized as follows. Worldwide procedures grew by approximately 14%. We shipped 492 da Vinci Surgical Systems in the year, up from 431 in 2014. Total revenue was $2.4 billion, up 12% from 2014 and up 15% on a constant currency basis. Recurring revenue grew to $1.7 billion, up 11% and comprising 70% of total revenue. We generated $946 million in pro forma operating profit, up 16% from last year. Pro forma net income was $731 million, up 20% from 2014. And we repurchased 366,000 shares at an average price of $502 per share during 2015.

    回顧 2015 年全年,我們的營運表現摘要如下。全球手術量成長約 14%。全年出貨 492 套達文西手術系統,高於 2014 年的 431 套。總營收為 24 億美元,較 2014 年成長 12%,以固定匯率計算成長 15%。經常性收入成長至 17 億美元,成長 11%,佔總營收 70%。我們產生 9.46 億美元的擬制(pro forma)營業利益,較去年成長 16%。擬制淨利為 7.31 億美元,較 2014 年成長 20%。此外,我們在 2015 年以每股平均 502 美元的價格回購 366,000 股。

  • Turning to our operating performance for the fourth quarter, procedures grew approximately 15% over the fourth quarter of last year. We shipped 158 da Vinci Surgical Systems, up from 137 in the fourth quarter of 2014. Total pro forma revenue for the quarter was $677 million, up 13% from prior year. Instrument and accessory revenue increased to $326 million, up 16%. We generated a pro forma operating profit of $293 million in the quarter, up 28% from the fourth quarter of last year and pro forma net income was $224 million, up 22% from Q4 of 2014.

    接著看第四季的營運表現,手術量較去年第四季成長約 15%。我們出貨 158 套達文西手術系統,高於 2014 年第四季的 137 套。本季擬制總營收為 6.77 億美元,較去年同期成長 13%。器械與配件營收增加至 3.26 億美元,成長 16%。本季擬制營業利益為 2.93 億美元,較去年第四季成長 28%;擬制淨利為 2.24 億美元,較 2014 年第四季成長 22%。

  • As we look to the future, we passionately believe that robotic-assisted surgery is in its infancy in application and technology. As we have improved our cost and supply chains for new products, we anticipate increasing our investments in key areas that will enable and drive the future of robotic-assisted surgery. These include product investments in advanced imaging, advanced instrumentation and next-generation robotics. We will also continue to invest in procedure, product and program analytics, international market development, and economic and clinical validation.

    展望未來,我們堅信機器人輔助手術在應用與技術方面仍處於萌芽階段。隨著我們已改善新產品的成本結構與供應鏈,我們預期將加大在關鍵領域的投資,以促成並推動機器人輔助手術的未來發展。這些投資包括先進影像、先進器械以及下一代機器人等產品投資。我們也將持續投資於手術、產品與方案分析、國際市場開發,以及經濟與臨床驗證。

  • Looking to 2016, our priorities are as follows. First, we will focus on the expanded use of da Vinci in general and thoracic surgery, particularly colorectal surgery and hernia repair. Second, we will work to advance our ecosystem, including expanding our Xi line and taking our SP Product line into initial clinical use. Third, we will drive our organizational capabilities in markets in Europe and Asia and finally, we will continue to assist our customers in their efforts to maximize the comprehensive value of their programs. I'll now turn the call over to Marshall, who will review financial highlights.

    展望2016年,我們的優先事項如下。第一,我們將聚焦於擴大da Vinci在一般外科與胸腔外科的使用,特別是大腸直腸手術與疝氣修補。第二,我們將致力於推進我們的生態系統,包括擴展我們的Xi產品線,並讓我們的SP產品線進入初期臨床使用。第三,我們將強化在歐洲與亞洲市場的組織能力;最後,我們將持續協助客戶努力最大化其方案的整體價值。接下來我把電話交給Marshall,由他回顧財務重點。

  • Marshall Mohr - CFO

    Marshall Mohr - CFO

  • Thank you, Gary. I'll be describing our results on a non-GAAP, or pro forma basis, which excludes the impact of our prior-year Xi trade-in programs, legal settlements and legal claim accruals, stock-based compensation, amortization of purchased IP, and investment impairments. We provide pro forma information because we believe that business trends and operating results are easier to understand on a pro forma basis. I will also summarize our GAAP results later in my script. We posted reconciliations of pro forma results to our GAAP results on our website so that there is no confusion.

    謝謝你,Gary。我將以非GAAP(或備考)基礎說明我們的業績,該基礎排除前一年度Xi換購計畫、法律和解與法律索賠提列、以股票為基礎之酬勞、購買之智慧財產權攤銷,以及投資減損的影響。我們提供備考資訊,因為我們相信以備考基礎更容易理解業務趨勢與營運結果。我也會在講稿稍後摘要我們的GAAP結果。我們已在網站上公布備考結果與GAAP結果的調節表,以避免任何混淆。

  • Pro forma fourth quarter revenue was $677 million, an increase of 13% compared with $601 million for the fourth quarter of 2014 and an increase of 15% compared with last quarter. Pro forma revenue for the fourth quarter of 2014 excludes $4 million of revenue associated with offers made in 2014 to trade out SI product for Xi product. All trade-out offers were either fulfilled or lapsed in 2014.

    備考第四季營收為6.77億美元,較2014年第四季的6.01億美元成長13%,較上一季成長15%。2014年第四季的備考營收排除2014年提出以SI產品換購Xi產品之方案所相關的400萬美元營收。所有換購方案要約均已於2014年履行或到期失效。

  • Fourth quarter 2015 procedures of approximately 177,000 increased 15% compared with the fourth quarter of 2014, and increased 9% compared with the third quarter of 2015. Procedure growth was primarily driven by general surgery procedures in the US and urology worldwide. Revenue highlights are as follows: Pro forma instrument and accessory revenue increased 16% compared with last year and increased 9% compared with the third quarter of 2015. The increase relative to prior year reflects procedure growth and increased sales of advanced instruments partially offset by the impact of foreign exchange. The increase over the prior quarter reflects procedure growth and sales of advanced instruments, partially offset by customer buying patterns.

    2015年第四季手術量約177,000例,較2014年第四季增加15%,較2015年第三季增加9%。手術量成長主要由美國的一般外科手術以及全球的泌尿科手術所帶動。營收重點如下:備考器械與配件營收較去年增加16%,較2015年第三季增加9%。相較前一年之增加反映手術量成長與先進器械銷售增加,但部分被外匯影響所抵銷。相較前一季之增加反映手術量成長與先進器械銷售,但部分被客戶採購模式所抵銷。

  • Instrument and accessory revenue realized per procedure, including initial stocking orders, was approximately $1,840 per procedure. This metric has now been trending in a tight range between $1,830 and $1,840 per procedure over the past year with recent quarters reflecting higher sales of advanced instruments, offset by the impact of foreign exchange.

    每例手術實現的器械與配件營收(包含初始備貨訂單)約為每例1,840美元。過去一年此指標一直在每例1,830至1,840美元的狹窄區間內波動,近期季度反映先進器械銷售較高,但被外匯影響所抵銷。

  • Pro forma system revenue of $231 million increased 9% compared with last year and increased 32% compared with last quarter. The increase relative to the prior year primarily reflects increased unit sales. The increase relative to the third quarter reflects increased unit sales, partially offset by lower ASPs.

    備考系統營收為2.31億美元,較去年增加9%,較上一季增加32%。相較前一年之增加主要反映銷售台數增加。相較2015年第三季之增加反映銷售台數增加,但部分被較低的平均銷售價格(ASP)所抵銷。

  • 158 systems replaced in the fourth quarter compared with 137 systems in the fourth quarter of 2014, and 117 systems last quarter. Approximately 72% of the systems shipped in the quarter were Xi, which is comparable to prior quarters. Globally, our average system price of $1.550 million was comparable to the fourth quarter of 2014 and slightly less than the $1.600 million ASP last quarter. Relative to the prior year, increases related to a lower trade-in mix were mostly offset by foreign exchange. The decrease relative to the third quarter reflects geographic mix and a lower proportion of Xi dual consoles. ASPs fluctuate quarter to quarter based on geographic and product mix, trade-in volume and changes in foreign exchange rates.

    第四季更換(置換)系統158台,2014年第四季為137台,上一季為117台。本季出貨的系統約72%為Xi,與前幾季相當。全球平均系統價格為155萬美元,與2014年第四季相當,且略低於上一季160萬美元的ASP。相較前一年,因換購占比較低所帶來的提升大多被外匯所抵銷。相較2015年第三季之下降反映地理組合,以及Xi雙控制台占比較低。ASP會因地理與產品組合、換購量以及外匯匯率變動而在各季間波動。

  • Hospitals financed approximately 17% of the systems placed in the fourth quarter, down from 25% last quarter. We directly financed 20 systems, including placing the most operating leases, 16 since we began our direct leasing program in the second quarter of 2014. As of the end of the fourth quarter, 49 of the 3,597 systems out in the field were under operating leases. We exclude the impact of operating leases from our system ASP calculations.

    醫院為第四季所安裝(配置)的系統中約17%採用融資,低於上一季的25%。我們直接融資20台系統,其中包含最多的營業租賃配置;自2014年第二季開始直接租賃計畫以來,共有16台採營業租賃。截至第四季末,現場運行的3,597台系統中,有49台屬於營業租賃。我們在系統ASP計算中排除營業租賃的影響。

  • Service revenue of $120 million increased 9% year-over-year and increased 2% compared with the third quarter of 2015. The year-over-year and quarter-over-quarter increases reflect the increase in our installed base of da Vinci systems.

    服務營收為1.20億美元,年增9%,較2015年第三季增加2%。年增與季增主要反映我們da Vinci系統裝機基數的增加。

  • Outside of the US, results were as follows: Fourth quarter pro forma revenue outside of the US of $219 million increased 11% compared with $198 million for the fourth quarter of 2014 and increased 45% compared with $151 million last quarter. The increase compared with the previous year reflects higher system unit sales and higher recurring revenue driven by procedure growth of 27%. Outside the US, we placed 75 systems in the fourth quarter compared with 66 in the fourth quarter of 2014 and 37 systems last quarter. Current quarter system sales include 13 into China, 11 into Japan, 8 into Italy, and 7 into Brazil. System placements inside the US will continue to be lumpy, as some of these markets are in the early stages of adoption; some markets are highly seasonal, reflecting budget cycles or vacation patterns; and sales into some markets are constrained by government regulation.

    美國以外地區的結果如下:第四季美國以外地區備考營收為2.19億美元,較2014年第四季的1.98億美元增加11%,較上一季的1.51億美元增加45%。相較前一年之增加反映系統銷售台數較高,以及由手術量成長27%所帶動的較高經常性營收。在美國以外地區,我們第四季配置75台系統,2014年第四季為66台,上一季為37台。本季系統銷售包含:中國13台、日本11台、義大利8台、巴西7台。美國以外市場的系統配置將持續呈現不均勻(lumpy),因為其中部分市場仍處於採用初期;部分市場季節性強,反映預算週期或休假模式;且部分市場的銷售受政府法規限制。

  • The pro forma gross margin for the fourth quarter of 2015 was 69.6% compared with 67.1% for the fourth quarter of 2014 and 69.3% for the third quarter of 2015. Compared with the fourth quarter of 2014, the higher gross margin reflects lower inventory charges, improved efficiencies, partially offset by foreign exchange, and a higher mix of our newer products which carry lower gross margins than our mature products. Gross margin includes the impact of the medical device tax, which has been suspended for the next two years. The medical device tax reduced our 2015 gross margin by approximately 70 basis points. Future margins will fluctuate based on the mix of our newer products and whether we are required to pay the medical device tax and costs associated with manufacturing efficiencies and product charges.

    2015年第四季備考毛利率為69.6%,2014年第四季為67.1%,2015年第三季為69.3%。相較2014年第四季,較高的毛利率反映較低的存貨費用、效率提升,但部分被外匯影響所抵銷,且我們較新產品的占比提高(其毛利率低於成熟產品)。毛利率包含醫療器材稅的影響,該稅已暫停徵收未來兩年。醫療器材稅使我們2015年毛利率約降低70個基點。未來毛利率將隨較新產品的組合、是否需要繳納醫療器材稅,以及與製造效率與產品費用相關的成本而波動。

  • In 2014, we recorded pre-tax charges of approximately $82 million, representing the estimated cost of settling a number of product legal liability claims under a tolling agreement. During 2015, we refined our estimate of the overall cost of settling claims and recorded additional charges of approximately $14 million in the first half of the year. There were no charges in the second half of 2015. Charges made related to this agreement are excluded from our pro forma results and are included in our GAAP results.

    2014 年,我們記錄了約 8,200 萬美元的稅前費用,代表在一項中止時效協議下就多項產品法律責任索賠達成和解的估計成本。2015 年期間,我們精煉了對整體索賠和解成本的估計,並在上半年額外記錄了約 1,400 萬美元的費用。2015 年下半年沒有記錄任何費用。與該協議相關的已記錄費用已自我們的備考(pro forma)結果中排除,並納入我們的 GAAP 結果中。

  • As of the end of the fourth quarter $24 million remained accrued on our balance sheet as a significant portion of the estimated costs have been paid. Pro forma operating expenses, which exclude reserves for legal claims, stock compensation expense, and amortization of purchased IP increased 7% compared with the fourth quarter of 2014 and increased 6% compared with last quarter. The year-over-year increase of pro forma operating expenses primarily reflects headcount additions and higher incentive compensation. The increase relative to the third quarter primarily reflects increased incentive compensation.

    截至第四季末,由於估計成本中相當大的一部分已支付,我們的資產負債表上仍有 2,400 萬美元的應計負債。備考營業費用(不含法律索賠準備、股票薪酬費用及購入 IP 的攤銷)較 2014 年第四季增加 7%,較上季增加 6%。備考營業費用的年增主要反映人員編制增加以及較高的獎勵性薪酬。相較第三季的增加主要反映獎勵性薪酬提高。

  • Our pro forma effective tax rate for the fourth quarter was 24.9% compared with an effective tax rate of 23.5% for the fourth quarter of 2014 and 18.4% last quarter. The effective tax rate for the third quarter of 2015 included tax benefits of $29 million, or $0.77 per share, related to a recent favorable tax court ruling involving an independent third party. In late December, Congress renewed the Federal Research and Development Credit resulting in a benefit of $6 million, or $0.17 per share. Congress also made the R&D tax credit permanent so our 2016 rate guidance will reflect this benefit. Our tax rate will fluctuate with changes in the mix of the US and OUS income.

    我們第四季的備考有效稅率為 24.9%,相較 2014 年第四季的有效稅率 23.5% 以及上季的 18.4%。2015 年第三季的有效稅率包含 2,900 萬美元(每股 0.77 美元)的稅務利益,與近期一項涉及獨立第三方的有利稅務法院裁決相關。12 月下旬,國會延長了聯邦研發抵減(Federal Research and Development Credit),帶來 600 萬美元(每股 0.17 美元)的利益。國會亦將研發稅額抵減永久化,因此我們 2016 年的稅率指引將反映此項利益。我們的稅率將隨美國(US)與美國以外(OUS)所得組合的變化而波動。

  • Our fourth quarter 2015 pro forma net income was $224 million, or $5.89 per share, compared with $184 million, or $4.92 per share, for the fourth quarter of 2014, and $199 million, or $5.24 per share, for the third quarter of 2015. As I indicated earlier, pro forma income provides an easier comparison of our financial results and business trends.

    我們 2015 年第四季備考淨利為 2.24 億美元(每股 5.89 美元),相較 2014 年第四季的 1.84 億美元(每股 4.92 美元),以及 2015 年第三季的 1.99 億美元(每股 5.24 美元)。如我先前所述,備考盈餘能更容易比較我們的財務結果與業務趨勢。

  • I will now summarize our GAAP results. GAAP revenue was $677 million for the fourth quarter of 2015 compared with $605 million for the fourth quarter 2014 and $590 million for the third quarter of 2015. GAAP net income was $190 million, or $4.99 per share, for the fourth quarter of 2015 compared with $147 million, or $3.94 per share, for the fourth quarter of 2014, and $167 million, or $4.40 per share, for the third quarter of 2015.

    我現在將總結我們的 GAAP 結果。2015 年第四季 GAAP 營收為 6.77 億美元,相較 2014 年第四季的 6.05 億美元,以及 2015 年第三季的 5.90 億美元。2015 年第四季 GAAP 淨利為 1.90 億美元(每股 4.99 美元),相較 2014 年第四季的 1.47 億美元(每股 3.94 美元),以及 2015 年第三季的 1.67 億美元(每股 4.40 美元)。

  • We ended the year with cash and investments of $3.3 billion, up from $3.1 billion as of September 30, 2015. The increase was primarily driven by cash generated from operations and proceeds from stock option exercises, partially offset by stock buybacks. During the quarter, we repurchased approximately 167,000 shares for $84 million at an average price of $505 per share. This brings our total stock repurchases for 2015 to approximately $184 million. And with that, I'd like to turn it over to Patrick, who will go over our procedure and clinical highlights.

    我們以 33 億美元的現金與投資結束本年度,較 2015 年 9 月 30 日的 31 億美元增加。增加主要由營運產生的現金及員工行使股票選擇權的收入所帶動,部分被庫藏股回購所抵銷。本季期間,我們以每股平均 505 美元的價格回購約 167,000 股,金額為 8,400 萬美元。使得我們 2015 年全年股票回購總額約為 1.84 億美元。接下來,我想把時間交給 Patrick,他將說明我們的手術量與臨床重點。

  • Patrick Clingan - Senior Director, Finance

    Patrick Clingan - Senior Director, Finance

  • Thanks, Marshall. Total fourth quarter year-over-year procedures grew approximately 15%, with US procedures growing approximately 12%, and international procedures approximately 27%. Full-year 2015 procedure growth was approximately 14%, with US procedures growing approximately 11% and international procedures growing approximately 26%.

    謝謝你,Marshall。第四季手術總量年增約 15%,其中美國手術量年增約 12%,國際手術量約 27%。2015 年全年手術量成長約 14%,其中美國手術量成長約 11%,國際手術量成長約 26%。

  • In the US, fourth quarter procedure growth of approximately 12% was driven by continued strength in general surgery procedures with solid contribution coming from mature procedures despite already high levels of market penetration. We do not expect the strong 2015 growth in established US urology and gynecology procedures to continue in 2016.

    在美國,第四季手術量約 12% 的成長,主要由一般外科手術持續強勁所帶動;儘管市場滲透率已處高位,成熟手術仍有穩健貢獻。我們不預期 2015 年美國既有泌尿科與婦科手術的強勁成長會在 2016 年延續。

  • In US urology, fourth quarter growth in da Vinci prostatectomy and kidney cancer procedures continued at similar rates as earlier in the year. We continue to believe that our US prostatectomy volumes have been tracking to the broader prostate surgery market. In 2015, procedure growth in US urology was approximately 12%, led by an approximate 11% growth in da Vinci prostatectomy. We expect US da Vinci prostatectomy procedure volumes to return to a level more in line with prostate cancer incidence rates moving forward.

    在美國泌尿科方面,第四季達文西前列腺切除術與腎癌手術的成長率,與年初至今的水準相近。我們仍相信,美國前列腺切除術的手術量走勢與更廣泛的前列腺手術市場一致。2015 年,美國泌尿科手術量成長約 12%,其中達文西前列腺切除術約成長 11% 為主要帶動因素。我們預期,未來美國達文西前列腺切除術的手術量將回到更貼近前列腺癌發生率的水準。

  • In US gynecology, fourth quarter procedures grew modestly year over year, with growth in malignant and complex hysterectomy partially offset by declines in benign procedures. During 2015, a larger proportion of da Vinci hysterectomy procedures were performed by gynecologic oncologists compared to 2014. For the year, growth in US gynecology procedures was approximately 1%. In 2016, sustaining growth in US gynecology may be a challenge, as we believe the total market for benign hysterectomies will continue to decline at a low single-digit rate.

    在美國婦科方面,第四季手術量年增幅度溫和;惡性與複雜子宮切除術的成長,部分被良性手術量下滑所抵銷。2015 年,達文西子宮切除術中由婦科腫瘤專科醫師執行的比例較 2014 年更高。全年而言,美國婦科手術量成長約 1%。2016 年要維持美國婦科的成長可能具有挑戰,因為我們認為良性子宮切除術的整體市場將持續以低個位數的速度下滑。

  • Fourth quarter growth in US general surgery remained strong, with robust growth in hernia repair and continued adoption of colorectal procedures being partially offset by continued declines in cholecystectomies. US general surgery procedure growth was approximately 31% for the year with broad-based growth across several procedures led by hernia repair, which generated the largest number of new general surgery procedures. Growth in colorectal resections was also strong during 2015. In 2016, there remains a large opportunity in hernia repair and colorectal resections and driving adoption in these markets remains among our top priorities.

    第四季美國一般外科的成長仍然強勁;疝氣修補的強勁成長與結直腸手術的持續採用,部分被膽囊切除術持續下滑所抵銷。美國一般外科手術量全年成長約 31%,多項手術皆呈現廣泛成長,其中以疝氣修補為主,帶來最多新增的一般外科手術量。2015 年結直腸切除術的成長也相當強勁。2016 年,疝氣修補與結直腸切除術仍有龐大機會,在這些市場推動採用仍是我們的首要任務之一。

  • During the quarter, a group of general surgeons led by Dr. Vorst from St. Joseph's Mercy Health System, and Dr. Carbonell from the University of South Carolina School of Medicine published their perspective on advances in ventral and incisional hernia repair in the World Journal of Gastrointestinal Surgery.

    本季期間,由聖約瑟夫慈悲醫療體系(St. Joseph's Mercy Health System)的 Vorst 醫師領導的一群一般外科醫師,以及南卡羅來納大學醫學院(University of South Carolina School of Medicine)的 Carbonell 醫師,在《World Journal of Gastrointestinal Surgery》發表了他們對腹壁與切口疝氣修補進展的觀點。

  • Within the paper, data comparing the robotic to open Rives-Stoppa technique for more complex hernias favored the robotic approach with a reduction in blood loss, shorter length of hospital stay, fewer surgical site infections, and no difference in operative times or direct costs. The paper states that robotic approach, quote -- permits relatively easy access to the interior abdominal wall, allowing the surgeon to perform the ideal repair for that patient. It also might allow for standardization of surgical technique in order to develop a reliable approach to hernia repair that can be offered to an increasing number of patients -- close quote.

    在該論文中,針對較複雜疝氣,比較機器人手術與傳統開放式 Rives-Stoppa 技術的數據顯示,機器人方式更具優勢:出血量降低、住院天數縮短、手術部位感染較少,且手術時間或直接成本並無差異。論文指出,機器人方式,引用原文——「可相對容易地進入腹壁內側,使外科醫師能為該患者執行理想的修補。」並且也可能有助於手術技術的標準化,以建立一種可靠的疝氣修補方式,得以提供給愈來愈多的患者——引文結束。

  • Regarding our US single-site business, cholecystectomy volumes continued to decline during the fourth quarter, though mostly offset by a growth in multi-port cholecystectomies. In addition, our single-site gynecology procedure volumes declined in the fourth quarter. Taken together, single-site procedures represented less than 5% of our fourth quarter US procedure volume. Looking abroad during the fourth quarter, the approximate 27% international procedure growth was led by the global adoption of da Vinci prostatectomy, with solid contributions from kidney procedures, malignant hysterectomies and colorectal resections. For the full-year, procedure growth was approximately 26%.

    關於我們在美國的單孔(single-site)業務,第四季膽囊切除術量持續下滑,但多孔(multi-port)膽囊切除術的成長在很大程度上抵銷了這一影響。此外,我們的單孔婦科手術量在第四季也有所下降。綜合而言,單孔手術占我們第四季美國手術量的比例不到 5%。放眼海外,第四季約 27% 的國際手術量成長主要由達文西前列腺切除術在全球的採用所帶動,腎臟手術、惡性子宮切除術與結直腸切除術亦有穩健貢獻。全年而言,手術量成長約為 26%。

  • Procedure growth in Europe remained steady throughout 2015. In Asia, procedure growth was led by a broad-based adoption China and South Korea and da Vinci prostatectomy adoption in Japan. During 2016, we expect several external factors to impact international procedure growth. In Japan, the Surgical Society has submitted for reimbursement of partial nephrectomies to the MHLW. Pending the MHLW's decision this may serve as a tail-end to Japanese procedure growth. In China, we have placed 32 of the 38 da Vinci systems under the current authorization. And sustaining strong procedure growth throughout 2016 may require additional authorizations from the government.

    歐洲的手術量成長在 2015 年全年維持穩定。在亞洲,手術量成長主要由中國與南韓的廣泛採用,以及日本對達文西前列腺切除術的採用所帶動。在 2016 年期間,我們預期若干外部因素將影響國際手術量成長。在日本,外科學會已向厚生勞動省(MHLW)提交部分腎切除術的健保給付申請。視 MHLW 的決定而定,這可能成為日本手術量成長的尾端動能。在中國,我們已在現行核准額度下完成 38 套達文西系統中的 32 套裝機。而要在 2016 年全年維持強勁的手術量成長,可能需要政府核發額外的核准。

  • During the quarter, the global evidence for the cost-effectiveness for the use of da Vinci surgery in gynecologic oncology continued to build. A new study from Copenhagen University Hospital by [Dr. Hurley] and colleagues modeled the clinical and economic impact of the adoption of da Vinci for malignant hysterectomies, capturing the comprehensive cost of care associated with these interventions. The study compared 158 open hysterectomies to 202 da Vinci hysterectomies. We found the da Vinci hysterectomies were 17% less expensive than open hysterectomies based on operating costs, and 7% less expensive than open hysterectomies when the da Vinci System cost was included. The study found the cost savings associated with fewer complications and shorter hospitalization more than offset the incremental cost associated with the use of da Vinci technology in the operating room.

    本季期間,關於在婦科腫瘤領域使用達文西手術之成本效益的全球證據持續累積。哥本哈根大學醫院由 [Dr.Hurley] 及其同事發表的一項新研究,針對採用達文西進行惡性子宮切除術的臨床與經濟影響建立模型,並納入與這些介入相關的整體照護成本。該研究比較了 158 例開腹子宮切除術與 202 例達文西子宮切除術。我們發現,以手術室作業成本計算,達文西子宮切除術較開腹子宮切除術便宜 17%;若將達文西系統成本納入,達文西子宮切除術仍較開腹子宮切除術便宜 7%。研究指出,因併發症較少與住院時間較短所帶來的成本節省,足以抵銷在手術室使用達文西技術所增加的邊際成本。

  • 2015 was a robust year for clinical publications featuring da Vinci surgery, with over 1,600 papers published during the year, bringing total clinical publications to over 10,000. This concludes my remarks and thank you for your time. I will now turn the call over to Calvin.

    2015 年是以達文西手術為主題之臨床論文發表相當強勁的一年,全年發表超過 1,600 篇,使臨床發表總數累計超過 10,000 篇。以上為我的發言,感謝各位撥冗。接下來我把電話交給 Calvin。

  • Calvin Darling - Senior Director of Finance and IR

    Calvin Darling - Senior Director of Finance and IR

  • Thank you, Patrick. I will be providing you with our financial outlook for 2016. Starting with procedures. As described in our announcement last week, 2015 total da Vinci procedures grew approximately 14% to roughly 652,000 procedures performed worldwide. During 2016, we anticipate full-year procedure growth within a range of 9% to 12%. We expect similar seasonal timing of procedures in 2016 as we've experienced in previous years, with Q1 being the seasonally weakest quarter as patient deductibles are reset.

    謝謝你,Patrick。我將為各位提供我們對 2016 年的財務展望。先從手術量談起。如同我們上週公告所述,2015 年達文西手術總量約成長 14%,全球執行約 652,000 例手術。在 2016 年,我們預期全年手術量成長落在 9% 至 12% 的區間。我們預期 2016 年手術量的季節性時點將與過往年度相近,其中第一季通常為季節性最弱的一季,因為病患自付額會重置。

  • With respect to revenue, we expect 2016 capital sales to follow historical seasonal patterns, which we anticipate will become more pronounced, with Q1 being sequentially lower than the recently completed Q4. System placements will likely continue to be lumpy, particularly in markets outside of the US, as some of these markets are in early stages of adoption. Some markets are highly seasonal, reflecting budget cycles or vacation patterns and sales into some markets are constrained by government regulations.

    就營收而言,我們預期 2016 年資本設備銷售將遵循歷史季節性型態,且我們預期此季節性將更為明顯,第一季將較剛結束的第四季呈現季對季下滑。系統裝機量可能仍將呈現不均勻(lumpy),尤其是在美國以外的市場,因其中部分市場仍處於採用的早期階段。部分市場具有高度季節性,反映預算週期或假期型態;此外,對某些市場的銷售亦受政府法規限制。

  • Turning to gross profit. We expect our 2016 pro forma gross profit margin to be within a range of between 68% and 69.5% of net revenue. Our actual gross profit margin will vary quarter to quarter, depending largely on product and regional mix.

    接著談毛利。我們預期 2016 年備考(pro forma)毛利率將落在淨營收的 68% 至 69.5% 之間。我們的實際毛利率將隨季度而變動,主要取決於產品組合與區域組合。

  • Turning to operating expenses. As Gary mentioned, we will be increasing our investments in key areas that will enable and drive the future of robotic-assisted surgery. We expect to grow 2016 operating expenses between 9% and 13% above 2015 levels. We expect our non-cash stock compensation expense to range between $170 million and $180 million in 2016 compared to $168 million in 2015. We expect other income, which is comprised mostly of interest income to total between $20 million and $25 million in 2016.

    接著談營業費用。如 Gary 所提到,我們將增加對關鍵領域的投資,以促成並推動機器人輔助手術的未來發展。我們預期 2016 年營業費用將較 2015 年成長 9% 至 13%。我們預期 2016 年非現金的股票酬勞費用將介於 1.70 億至 1.80 億美元之間,2015 年為 1.68 億美元。我們預期其他收入(主要由利息收入構成)在 2016 年合計將介於 2,000 萬至 2,500 萬美元之間。

  • With regard to income tax, we expect our 2016 pro forma income tax rate to be between 26.5% and 28.5% of pre-tax income, depending primarily on the mix of US and OUS profits. This forecast does reflect the reinstatement of the R&D tax credit in 2016. That concludes our prepared remarks. We will now open the call to your questions.

    關於所得稅,我們預期 2016 年備考所得稅率將介於稅前所得的 26.5% 至 28.5% 之間,主要取決於美國與美國以外(OUS)獲利的組合。此預測確實反映 2016 年研發(R&D)稅額抵減的恢復。以上為我們事先準備的發言。接下來我們將開放提問。

  • Operator

    Operator

  • (Operator Instructions)

    (接線生指示)

  • David Roman with Goldman Sachs.

    高盛(Goldman Sachs)的 David Roman。

  • David Roman - Analyst

    David Roman - Analyst

  • Thank you. Good evening everybody.

    謝謝。各位晚安。

  • I wanted to start with one strategic question and one follow-up on the financial guidance Calvin just provided. Maybe on the strategic side, I was hoping, Gary, you could go into your thoughts as it relates to the competitive landscape in robotics.

    我想先問一個策略性問題,並就 Calvin 剛提供的財測再追問一個問題。先從策略面來看,我希望 Gary 你能談談你對機器人領域競爭態勢的看法。

  • We've heard over the past several months, and now since from a couple of emerging competitors and there's an expected announcement from another competitor later in 2016. Can you maybe talk about how you envision the competitive landscape unfolding and some of the activities you may be undertaking to prepare Intuitive from moving one a monopoly-type market to one that has multiple players?

    過去幾個月我們聽到一些新興競爭者的消息,而另外一家競爭者也預計在 2016 年稍晚發布公告。你能否談談你如何看待競爭格局的演變,以及你們可能採取哪些行動,來讓 Intuitive 為從類似壟斷的市場走向多家業者競爭的市場做好準備?

  • Gary Guthart - President & CEO

    Gary Guthart - President & CEO

  • Sure.

    當然。

  • As we look out at value and competition, at the end of the day, value is going to be driven by the ability of these products and services to drive and create outcomes and compare or weigh it against the price of those things. We think about it as an ecosystem. We think the ecosystem is really important, so it's easy to think just about the robotic systems because that's the most visible part. But there's the systems, the instruments and accessories, the advanced instrumentation, like stapling, imaging systems for us in imaging, training technologies like simulators and dual console, clinical validation, training courses offered by academic surgeons, that number in the dozens.

    當我們展望價值與競爭時,歸根結底,價值將由這些產品與服務推動並創造臨床結果的能力所驅動,並與其價格進行比較或權衡。我們把它視為一個生態系。我們認為生態系非常重要,因此人們很容易只想到機器人系統,因為那是最顯眼的部分。但除此之外,還包括系統本身、器械與配件、進階器械(例如縫合釘合 stapling)、影像系統(對我們而言是影像)、訓練技術(如模擬器與雙主控台)、臨床驗證,以及由學術外科醫師提供、數量達數十種的訓練課程。

  • That whole set of products in ecosystem what we think is important, and so as competitive enter, they have to choose. Can they show that value in terms of outcomes in price and can they offer this set of ecosystem elements that are going to be useful. We've known for years and have anticipated for years. We didn't wake up yesterday and think competitors are coming, we better to do something. So we've been thoughtful about what we need to do to create value for our customers.

    我們認為,生態系中的整套產品組合很重要;因此當競爭者進入時,他們必須做出選擇。他們能否在結果與價格的對照下證明其價值,並且能否提供這一整套有用的生態系要素。我們多年來一直知道並且預期會有競爭。我們不是昨天才醒來想到競爭者要來了、我們得做點什麼。因此,我們一直審慎思考需要做些什麼,才能為客戶創造價值。

  • We have a range of products in the system side that hits different price points for different feature content. We have different options that are available in terms of instrumentation price points, and so we think we're really well-positioned.

    我們在系統端有一系列產品,可針對不同功能內容覆蓋不同的價格帶。在器械(instrumentation)的價格帶方面,我們也有不同可選方案,因此我們認為自身的定位非常有利。

  • There are some other companies out there that will be capable. We expect that customers will explore what they're offering. We think we're well-positioned when that exploration occurs.

    市場上也有一些其他公司具備能力。我們預期客戶會去了解他們所提供的方案。我們認為在客戶進行這些評估時,我們的定位會很有利。

  • David Roman - Analyst

    David Roman - Analyst

  • Okay, that's helpful and then maybe just to go into the financial side for a second. I want to understand what you're saying on the margins for 2016. The gross margin range seems to imply that on an underlying basis when you take out the benefit of the medical device tax you're seeing a deterioration from where you exited the second half of 2015.

    好的,這很有幫助。接著我想稍微談一下財務面。我想了解你們對2016年毛利率的說法。毛利率區間看起來意味著,若剔除醫療器材稅帶來的好處,你們在基礎層面上看到的表現,較2015年下半年結束時的水準有所惡化。

  • What are the factors influencing that math? And then on the OpEx side, the 9% to 13% represents a pretty decent acceleration from what we saw this year. Can you maybe help put some of those investments into context? Where those dollars are going and whether 2016 represents a new normal year of investment spending or there's something particular that you're after this year?

    有哪些因素在影響這個推算?另外在營業費用(OpEx)方面,9%到13%代表相較於今年我們看到的水準有相當明顯的加速。你能否協助把這些投資放到脈絡中說明?這些資金會用到哪裡,以及2016年是否代表投資支出進入新的常態,或是今年有特定目標要達成?

  • Marshall Mohr - CFO

    Marshall Mohr - CFO

  • Sure, David. I'll will take you through some of the gross profit commentary and let Gary take you through some of the investments on the OpEx side. Like Gary said on the call, we're focused on reducing our cost of the new products and we've been managing our fixed costs very carefully.

    當然可以,David。我先帶你看一些毛利的說明,接著讓Gary說明營業費用端的投資。如同Gary在電話會議中提到的,我們專注於降低新產品成本,並且非常謹慎地管理固定成本。

  • We are pleased with the progress we've been making throughout 2015. Our second half 2015, gross profit benefited from favorable product mix: essentially zero product charges and other favorable outcomes. In 2016, we do expect to deliver continued cost reductions on the newer products including the Xi, Stapler, Vessel Sealer and Xi endoscopes.

    我們對2015年整體進展感到滿意。2015年下半年的毛利受惠於有利的產品組合:基本上沒有產品費用(product charges),以及其他有利因素。2016年,我們確實預期會在較新產品上持續交付成本降低,包括Xi、Stapler、Vessel Sealer以及Xi內視鏡。

  • At the same time, as compared to the second half of 2015, we'd expect a higher proportion of 2016 sales to be of the newer products. We'd expect a lower proportion of dual console systems sales, probably a higher proportion of system sales involving trade-ins and probably some product charges.

    同時,與2015年下半年相比,我們預期2016年銷售中較新產品的占比會更高。我們預期雙控制台系統(dual console systems)的銷售占比會較低,系統銷售中涉及以舊換新(trade-ins)的占比可能較高,並且可能會有一些產品費用(product charges)。

  • At some point, may be more in-line with historical norms from the past and while FX is not likely to be a strong a headwind as it was in 2015, it does appear as though it will have some negative impact on revenue and margins. And then lastly, I'd say from the competitive side, any pressure there, the impacts of that are unknown at this stage.

    在某個時間點,可能會更接近過去的歷史常態;此外,雖然匯率(FX)不太可能像2015年那樣形成強勁逆風,但看起來仍會對營收與毛利率帶來一些負面影響。最後我想說,從競爭面來看,若有任何壓力,其影響在現階段仍不明朗。

  • Gary Guthart - President & CEO

    Gary Guthart - President & CEO

  • On the investment side, as I mentioned in the script, we think that there is significant opportunity to improve what surgeons can see during cases, improving imaging for a variety of means technologically and we have been working on that for years and we will continue to do so. I think there's great potential there.

    在投資方面,如我在講稿中提到的,我們認為在提升外科醫師於手術中可視內容方面有很大的機會,也就是透過多種技術手段改善影像;我們已經投入多年,並將持續投入。我認為那裡有很大的潛力。

  • On the instrumentation side, we are expanding our stapling line and our advanced synergy lines, the reception has been quite good. Those are not single instruments; they are really families of instruments and we are filling out those families as we go. We feel good about it and think it's important.

    在器械方面,我們正在擴充縫合器(stapling)產品線以及我們的進階Synergy產品線,市場反應相當不錯。那些不是單一器械;它們其實是一整個器械家族,而我們會在推進過程中逐步補齊這些家族的產品組合。我們對此感到樂觀,並認為這很重要。

  • And we will continue to invest there and we think that there are opportunities in robotics in terms of both structure, things like SP and other things that can change different segments of the market that can allow us to enter other procedures that we're not currently in today or access other regions of the world that may have different needs. And so we will continue to invest in those things.

    我們也會持續在這方面投資;同時我們認為在機器人領域也存在機會,無論是在架構上,例如SP,以及其他能改變不同市場區隔的事物,讓我們能進入目前尚未涉足的其他術式,或觸及世界上可能有不同需求的其他地區。因此我們會持續投資這些方向。

  • David Roman - Analyst

    David Roman - Analyst

  • Okay. I appreciate all the detail. Thank you.

    好的。我很感謝你們提供的所有細節。謝謝。

  • Operator

    Operator

  • David Lewis with Morgan Stanley.

    Morgan Stanley的David Lewis。

  • David Lewis - Analyst

    David Lewis - Analyst

  • Good afternoon. So I want to come back to margins here for a second. The spread on margins and Marshall and Calvin, are $68 to $69.50, it's a wider spread. I don't think you gave us this spread last year.

    午安。我想再回到毛利率這個議題一下。毛利率區間的跨度,Marshall和Calvin,是68到69.50美元,這個跨度更大。我記得去年你們沒有給我們這樣的區間跨度。

  • What defines the upper end and lower end of those ranges and secondarily, when I think about these product manufacturing improvements you're making, we seem to have a substantial impact on gross margins in the second half of the year. I would presume those advantages or those costs would be a bigger tailwind in 2016 over 2015; is that a correct statement? Those two questions and I have a quick follow-up.

    這些區間的上緣與下緣是由什麼因素決定?其次,當我思考你們正在進行的這些製造端改善時,我們似乎在下半年看到對毛利率有顯著影響。我會推測這些優勢或成本因素在2016年相較於2015年會形成更大的順風;這樣的說法正確嗎?以上兩個問題,另外我還有一個簡短追問。

  • Gary Guthart - President & CEO

    Gary Guthart - President & CEO

  • To characterize the cost reductions, they had some impact in the second half of 2016. They -- or 2015, sorry. They will have a more significant impact than 2016 and 2017. And we -- as Calvin had said, we will continue to focus on reducing the costs. I think the bigger improvement during 2015 had to do with the lack of product charges that we mentioned in Q1.

    就成本降低來說,它們在2016年下半年有一些影響。它們——或是2015年,抱歉。它們在2016年與2017年的影響會更顯著。而且我們——如同Calvin所說——會持續專注於降低成本。我認為2015年較大的改善,主要與我們在第一季提到的產品費用(product charges)缺乏有關。

  • And as we move forward, the range is really -- or the breadth of the range is really reflective of the items that Calvin gave you, which is that we expected to see a higher proportion of newer products. The extent of that we will see.

    而展望未來,區間——或區間寬度——主要反映了Calvin剛才提到的那些項目,也就是我們預期較新產品的占比會更高。至於實際會提高到什麼程度,仍有待觀察。

  • We expect to see a lower proportion of dual consoles and a higher proportion of trade-ins. The mix of systems is always difficult to predict and frankly, geographic mix also has an implication here. As I said in my script, there's quite a bit of lumpiness to some of the geographic market.

    我們預期雙控制台的占比會較低、以舊換新(trade-ins)的占比會較高。系統產品的組合一向難以預測,坦白說,地理區域組合也會在此產生影響。如我在講稿中所說,部分地區市場的需求波動(lumpiness)相當明顯。

  • David Lewis - Analyst

    David Lewis - Analyst

  • Okay and then Gary, just a quick strategic and margin question for you, as well. So, the expenses we saw a couple years ago, you made a selective decision to just reinvest. Is that a -- this is a 50% increase in OpEx spending relative to 2015. 400 basis points to 500 basis points above.

    好的。接著Gary,我也有一個快速的策略與毛利率問題。幾年前在費用方面,你們做了選擇性決策,決定把資源再投資。這次——相較於2015年,營業費用(OpEx)支出增加了50%。高出400到500個基點。

  • Is it -- do you see this similarly as the opportunity to reinvest and is the investment spend heavier on SG&A or R&D? And the follow-up is just on SP, as you mentioned, in light of what is happening with single-site procedures, does that change your thinking of the opportunity around SP? Sorry for the couple questions there. Thank you.

    你是否也把這視為再投資的機會?而投資支出是偏向SG&A還是R&D較多?另外追問一下關於SP:如你提到的,鑑於單孔(single-site)手術目前的情況,這是否會改變你對SP機會的看法?抱歉一次問了幾個問題。謝謝。

  • Gary Guthart - President & CEO

    Gary Guthart - President & CEO

  • Sure. In terms of the balance of investments, it really is targeted in a couple areas. R&D is clearly one area that we'll get investment. And then support for international markets and some of those things are more structural, not necessarily just sales folks but clinical trials and other things.

    當然。就投資的配置而言,主要鎖定在幾個領域。研發(R&D)顯然是我們會加大投資的一個領域。另外還包括對國際市場的支援,而其中一些更偏結構性投入,不一定只是增加銷售人員,也包括臨床試驗及其他事項。

  • That's where the balance or the bulk of that increase is going to lay, and we think we have technologies that are important and we think we have process that we can bring that's important and that will serve us well in the long-term and in the future. With regard to SP, these are the single-site. We think that SP enters and adds value in a different place than single-site does. Single-site tended to work on a little bit more limited workspace, a little bit more constrained set of procedures. SP is both broader and more capable.

    這就是那項增長的平衡點或主要增量將會落在的地方;我們認為我們擁有重要的技術,也認為我們有重要的流程可以導入,而這些在長期與未來都將對我們非常有利。至於 SP,這些是單一切口(single-site)。我們認為 SP 進入並創造價值的位置,與單一切口不同。單一切口往往是在較受限的工作空間、較受限制的一組手術程序中運作。SP 的範圍更廣、能力也更強。

  • Price points are a little bit different. So we think about SP, when we think trans-oral, trans-anal, colorectal, places where there's specimen removal. So we look at those things, and we think about it. SP is less oriented towards cosmetic benefits and more oriented towards being able to reach complex structures where you need to.

    價格帶也有些不同。因此我們在思考 SP 時,會想到經口、經肛、結直腸等有標本取出(specimen removal)的部位。所以我們會看這些面向並加以思考。SP 較不著重於外觀美容效益,而更著重於能夠到達你需要觸及的複雜結構。

  • David Lewis - Analyst

    David Lewis - Analyst

  • Thank you very much.

    非常感謝。

  • Operator

    Operator

  • Tao Levy with Wedbush.

    Wedbush 的 Tao Levy。

  • Tao Levy - Analyst

    Tao Levy - Analyst

  • Great. Thanks. Good afternoon. So maybe we can start with US system utilization. When you do the math, you're reaching peak levels here in the US in terms of averages. What's the dynamic currently in the marketplace whereby hospitals or -- could potentially accelerate the addition of new systems in order to, again, meet your procedure growth expectations that you've laid out?

    很好。謝謝。下午好。那我們或許可以先從美國系統使用率談起。如果你做一下計算,就平均值而言,你們在美國已經接近峰值水準。目前市場上的動態是什麼,使得醫院或——可能會加速新增系統,以再次符合你們所提出的手術量成長預期?

  • Gary Guthart - President & CEO

    Gary Guthart - President & CEO

  • Yes, I think as we've laid out -- make sure I interpret the question right. I think as we look at utilization patterns, one thing is important to remember in the United States -- around the world but in US as well is, there is not a single customer profile that fits them all. So the average does not cover all the endpoints.

    是的,我想就我們所說的——先確保我正確理解問題。我想當我們看使用率型態時,有一點很重要:在美國——其實全球也是,但在美國同樣如此——並不存在一種客戶樣貌可以適用所有人。所以平均值無法涵蓋所有端點。

  • We definitely see some integrated delivery networks who are very interested in optimizing procedures per system per year. Trying to drive that up to get better capital utilization and we will help them do that. We see other health systems that may be in the exact same market who are really interested in driving convenience for patients and for their surgeons, and are willing to invest in capital once they get to a minimum hurdle rate for procedure utilization.

    我們確實看到一些整合式醫療服務網路(integrated delivery networks)非常有興趣去最佳化每套系統每年的手術量。他們試圖把這個數字拉高,以提升資本使用效率,而我們也會協助他們做到。我們也看到其他可能在同一市場的醫療體系,他們更在意為病患與外科醫師帶來便利性;一旦手術使用率達到最低門檻(hurdle rate),他們就願意投入資本。

  • We see both. Predicting which of those strategies is going to dominate into the year is always a little bit hard. At the end of the day, we really focus the organization on great utilization and great support, whichever our customer wants to take us down.

    兩種情況我們都看得到。要預測哪一種策略在一年之內會成為主流,總是有點困難。但歸根結底,我們會讓組織聚焦在高使用率與高品質支援上,無論客戶希望我們走哪一條路。

  • Tao Levy - Analyst

    Tao Levy - Analyst

  • Okay, great. Just my follow-up. You've talked a couple of times about investing more and more into imaging. Aside from Firefly, we haven't seen anything very significant come out of the Company. So maybe you could highlight a couple of the interesting projects within imaging that we should be paying attention to. Thanks.

    好的,很好。我再追問一下。你們多次談到會在影像方面投入越來越多。除了 Firefly 之外,我們還沒看到公司推出任何非常重大的成果。所以也許你可以點出影像領域中幾個值得我們關注的有趣專案。謝謝。

  • Gary Guthart - President & CEO

    Gary Guthart - President & CEO

  • Sure. I think -- first statement is, I beg to differ, but I look at the imaging platform that we brought out with Xi and it's fundamentally different technology basis: distal chip imaging. It gives us room to do some things from usability reach and workflow point of view that were very hard to do otherwise. And so we continue down that pathway.

    當然。我想——第一點是,我不太同意這個說法;因為我看我們隨 Xi 推出的影像平台,它在技術基礎上是根本不同的:遠端晶片成像(distal chip imaging)。它讓我們在可用性、可達性與工作流程等面向,有空間去做一些原本很難做到的事。因此我們會持續沿著這條路走下去。

  • So for example, in Xi, you can move the scope arm to arm. There's not a dedicated robot to hold one endoscope so that gave you the idea of corehopping, the ability to look around the abdomen differently. The other thing that distal chip imaging gets you is the ability to articulate your endoscope, which is a part of the SP product line is endoscopic articulation.

    例如在 Xi 上,你可以把鏡頭臂在不同手臂之間移動。不需要一個專用機器人去固定某一支內視鏡,這也帶來了所謂的「corehopping」概念,也就是能以不同方式在腹腔內環視。遠端晶片成像帶來的另一個好處,是能讓你的內視鏡做關節式彎折(articulate);而這也是 SP 產品線的一部分,也就是內視鏡關節化。

  • We continue to invest in that set of technologies and expand our leadership position there because I think that both, you can get better image quality and more flexibility and better price points by doing that technology. That's one set of investments.

    我們會持續投資這一組技術並擴大我們在該領域的領先地位,因為我認為透過這項技術,你可以獲得更好的影像品質、更高的靈活性,以及更好的價格帶。這是一組投資方向。

  • The other set is, as you mentioned, with Firefly, the ability to look and see things that you can't see easily with a white light. The ability to look and see beneath tissue or to highlight tissue structure and they're a set of technologies there that are useful and we're investing in. But those are longer term. They take a while to develop and as we get further down the pipeline, we will share with you where we are.

    另一組投資,如你提到的 Firefly,是能夠看到用白光不容易看見的東西。例如能夠看見組織下方,或凸顯組織結構;那裡有一系列有用的技術,我們正在投入。但那些是較長期的。它們需要一段時間開發;當我們在研發管線上走得更深入時,我們會與你分享目前進展。

  • Tao Levy - Analyst

    Tao Levy - Analyst

  • Great. Thank you.

    很好。謝謝。

  • Operator

    Operator

  • Ben Andrew with William Blair.

    William Blair 的 Ben Andrew。

  • Ben Andrew - Analyst

    Ben Andrew - Analyst

  • Good afternoon. Thanks for taking the questions. On the initial SP use, Gary, that you talked about and you listed a few applications there. Should we assume that's where we will see some initial clinical work and when might we see results from those either published or discussed? Is that later this year, next year that maybe leads to next steps of commercializing the product?

    下午好。謝謝讓我提問。關於你提到的 SP 初期使用情境,Gary,你列出了一些應用。我們是否可以假設,初期的臨床工作會先從那些領域開始?而我們大概何時能看到相關結果被發表或被討論?是今年稍晚、還是明年,進而帶動產品商業化的下一步?

  • Gary Guthart - President & CEO

    Gary Guthart - President & CEO

  • Right. Yes, in terms of the first question of those are places we are intending to explore, so colorectal and trans-oral. We will also explore other places in time, but those are our initial experience -- we expect to have our initial experiences. In terms of timelines, I'm not ready yet to tell you when in the year it will happen. We're still in conversations with regulatory bodies about the pathway and so as we get some clarity there then we will describe it to you later in the year.

    對。是的,就第一個問題而言,那些是我們打算探索的領域,例如結直腸與經口。我們也會隨時間探索其他領域,但那些是我們的初期經驗——我們預期會先累積初期經驗的地方。至於時間表,我目前還不準備告訴你會在一年中的何時發生。我們仍在與監管機構就法規路徑進行討論;等我們更清楚之後,會在今年稍晚再向你說明。

  • Ben Andrew - Analyst

    Ben Andrew - Analyst

  • Okay, and in that same vein, if you look out three or four years, can the SP platform be a material percentage of the Company's volumes? Or is this something that probably remains a niche given the price point and we shouldn't really think differently about the distribution in maybe 5% or 10%, if you will?

    好的,那同樣延伸這個問題,如果你往三到四年後看,SP 平台能否成為公司手術量中相當重要的比例?或者由於價格帶因素,這可能仍然是利基市場,我們不應該對分布有不同想法,例如大概就是 5% 或 10% 之類?

  • Marshall Mohr - CFO

    Marshall Mohr - CFO

  • I think that it offers surgeons a different way to think about getting into the body in a different approach. It can deliver a lot of capability in a small package, parallel into the body and it can move about the body quite easily in terms of multi-quadrant access.

    我認為它為外科醫師提供了一種不同的方式,去思考以不同的進入路徑進入人體。它能在小巧的封裝中提供大量能力,以平行方式進入體內,並且在多象限(multi-quadrant)進入方面,能相當容易地在體內移動。

  • So I think it's hard to predict long-term. I think for sure, near term, there are niches that I think it matters. Whether those niches grow into bigger opportunities, I think remains to be seen. Having said that, the history of Intuitive and the history of technology is that as you bring raw technology into the hands of experts and they start to use it and develop it a way leads to way.

    所以我認為很難預測長期情況。我認為可以確定的是,短期內確實有一些利基領域,我覺得它很重要。至於這些利基是否會成長為更大的機會,我想仍有待觀察。不過話說回來,Intuitive 的歷史以及科技的歷史都顯示,當你把原始技術交到專家手上,他們開始使用並加以發展時,往往會一條路帶出另一條路。

  • And I believe that. I think that we will see things that develop as surgeons get deep with it. How big that gets? Impossible to predict right now.

    我相信這一點。我認為,隨著外科醫師更深入地使用它,我們會看到一些發展。會變得多大?目前還無法預測。

  • Ben Andrew - Analyst

    Ben Andrew - Analyst

  • Okay and then lastly, for me. Thank you for taking the questions, by the way. The range of procedure guidance is a little wide to start the year, obviously. And let's just try to isolate one, in fact, if we can. China. So if we don't see another authorization for system sale, is that a material impact within the range? Is that a percentage point or 2 percentage points in terms of a potential swing? Or how should we look at the example of China specifically?

    好的,最後一個問題,就我這邊。順帶一提,謝謝你們回答問題。很明顯,年初對手術量指引的區間有點寬。我們就試著聚焦在一個項目,事實上如果可以的話。中國。所以如果我們沒有看到另一項系統銷售的核准,這在該區間內會造成實質影響嗎?就潛在波動而言,這是 1 個百分點或 2 個百分點嗎?或者我們應該如何特別看待中國這個例子?

  • Marshall Mohr - CFO

    Marshall Mohr - CFO

  • Thanks for the question, Ben.

    謝謝你的問題,Ben。

  • When it comes to procedure guidance, our focus is going to continue to be on driving growth in general surgery in our international markets including China. When you look at the breadth of the range to your question, there's far bigger impacts than just the system authorization in China. When it comes to the mature procedures in the US and the rates of growth that we may see there that benefited us in 2015. And certainly across a much wider range of markets.

    談到手術量指引,我們的重點將持續放在推動國際市場(包括中國)的一般外科成長。就你提到的區間寬度而言,影響遠不僅僅是中國的系統核准。還包括美國成熟手術量以及我們可能看到的成長率——這些在 2015 年對我們有利。而且當然也涵蓋更廣泛的一系列市場。

  • Ben Andrew - Analyst

    Ben Andrew - Analyst

  • Okay. Great. Thank you.

    好的。很好。謝謝。

  • Operator

    Operator

  • Matt O'Brien with Piper Jaffray.

    Piper Jaffray 的 Matt O'Brien。

  • JP Peltier - Analyst

    JP Peltier - Analyst

  • Hi everyone. This is actually JP in for Matt. Thanks for taking my questions. I just want to get back to the margin profile for next year and ask it in a more simpler way. So, if you exclude the 70 basis points that you gained from the med tax credit given the guidance you gave for OpEx next year, would we be expecting the adjusted EBIT margins to actually be down year over year?

    各位好。我是 JP,代替 Matt。謝謝你們回答我的問題。我想回到明年的利潤率輪廓,用更簡單的方式問。所以,如果排除你們因醫療器材稅抵免而增加的 70 個基點,考量你們對明年營業費用(OpEx)的指引,我們是否應該預期調整後 EBIT 利潤率會年減?

  • Marshall Mohr - CFO

    Marshall Mohr - CFO

  • I think there are lot of layered assumptions that go into the model and we don't have specific guidance that relates to that. Revenue would be one of the factors certainly underlying the overall assumptions there. I think what we tried to do is lay out a lot of the factors that would be impacting the gross margin, as well as investments we're making on the expense side.

    我認為模型中有很多層的假設,我們沒有針對那一點提供具體指引。營收當然會是支撐整體假設的因素之一。我想我們試著做的是,說明許多會影響毛利率的因素,以及我們在費用端所做的投資。

  • JP Peltier - Analyst

    JP Peltier - Analyst

  • Got it. And if I could ask one on the recent clearance for the Integrated Table Motion. How is that sale going to be, and how are you guys going to get revenue from that? Is that going to be sale from Trump's Medical and you have got a piece of the revenue, or how would that work?

    了解。如果我可以再問一個關於最近「整合式手術台移動(Integrated Table Motion)」核准的問題。那個銷售會怎麼進行,你們會如何從中取得營收?那會是由 Trump’s Medical 銷售、你們分得一部分營收,還是會怎麼運作?

  • Gary Guthart - President & CEO

    Gary Guthart - President & CEO

  • Trump will sell the Table in an independent transaction to the hospital. What we get out of it is we sell a software upgrade package for the table that allows it to be -- to operate it in an integrated fashion.

    Trump 會以獨立交易的方式把手術台賣給醫院。我們從中取得的是:我們會銷售一個針對該手術台的軟體升級套件,使其能夠——以整合的方式操作。

  • Marshall Mohr - CFO

    Marshall Mohr - CFO

  • I think for us, the key here is we're working to make the operation more efficient, right? This will make the ability for surgeons to reposition the patient without having to withdraw the robot arms to re-dock, doing a procedure, make it more efficient, and therefore benefit certain group of procedures and hopefully drive adoption in them. I think that's really the key benefit from our perspective.

    我想對我們而言,關鍵在於我們正在讓手術操作更有效率,對吧?這將讓外科醫師能夠在不必收回機器人手臂、重新對接(re-dock)的情況下重新調整病人姿勢,讓手術更有效率,因此有利於某些手術類別,並希望能推動其採用。我認為從我們的角度來看,這才是真正的關鍵效益。

  • JP Peltier - Analyst

    JP Peltier - Analyst

  • Great, thank you.

    很好,謝謝。

  • Operator

    Operator

  • Bob Hopkins from Bank of America.

    美國銀行(Bank of America)的 Bob Hopkins。

  • Bob Hopkins - Analyst

    Bob Hopkins - Analyst

  • Thanks and good afternoon. So, I wanted to ask a question about 2016 revenue growth to start. Can you give us a sense as to where you see incremental opportunities for acceleration? So what are the areas where you see your product categories, where you see the potential for accelerating revenue growth or entirely new growth drivers in 2016 versus what you experienced in 2015. And obviously, we're well aware of what the major growth drivers are. I'm curious about the things that potentially are available to you in 2016 that weren't available in 2015.

    謝謝,午安。我想先問一個關於 2016 年營收成長的問題。你們能否讓我們了解一下,你們認為有哪些額外機會可以加速成長?也就是說,在 2016 年,相較於 2015 年的表現,你們在哪些產品類別看到營收成長加速的潛力,或是全新的成長驅動因素?當然,我們很清楚主要的成長驅動因素是什麼。我好奇的是,2016 年有哪些你們可能掌握、但 2015 年尚未具備的機會。

  • Gary Guthart - President & CEO

    Gary Guthart - President & CEO

  • So we look at 2016 in a couple places. I think that we have opportunities in o-US markets in various places that are important to us. Now, there are some structural things that we have to overcome and invest in and sometimes there's reimbursement and sometimes there are other parts of market access. And we will do that, but I think the opportunity there is quite good.

    我們從幾個面向看 2016 年。我認為我們在美國以外(o-US)的市場,在多個對我們重要的地區都有機會。當然,有一些結構性的事情需要克服並投入資源,有時候是給付,有時候是市場准入的其他環節。我們會去做,但我認為那裡的機會相當不錯。

  • I think in terms of other verticals we are working on a 30-millimeter Stapler. The 30-millimeter Stapler is really targeted at thoracic procedures. Xi System design is -- has a -- part of its design intent was to facilitate thoracic procedures and we are in early days there. So as time goes on, I don't think that's something that's going to leap out of the gate in the beginning part of the year, but things we are investing in from a product and support point of view, that should build momentum over the next multiple quarters.

    我認為就其他垂直領域而言,我們正在開發一款 30 毫米吻合器(Stapler)。這款 30 毫米吻合器主要針對胸腔手術。Xi 系統的設計——其設計初衷的一部分就是為了促進胸腔手術,而我們目前仍在早期階段。因此,隨著時間推進,我不認為它會在年初就立刻大幅起量,但我們在產品與支援面所做的投資,應能在接下來多個季度逐步累積動能。

  • Bob Hopkins - Analyst

    Bob Hopkins - Analyst

  • Marshall, to follow-up on two quick things. On the revenue per procedure number and you highlighted that's been very stable within a range, but it feels like the cadence of new products will pick up as we move forward there. Can we expect that line item to start moving back up towards the old highs as we go forward here?

    Marshall,我想追問兩個簡短的問題。關於每例手術的營收(revenue per procedure),你提到它在一個區間內一直很穩定,但感覺未來新產品推出的節奏會加快。我們是否可以預期,隨著時間推進,這個項目會開始回升、朝向過去的高點?

  • And then the other quick thing I wanted to ask of you is that I appreciate the comment that 70% of revenues now come from disposables. Can you give us a rough sense as to what the relative profitability of that disposable stream is versus the capital side of the business?

    另外一個簡短問題是:我理解你提到目前 70% 的營收來自一次性耗材。你能否大致說明一下,這條耗材營收流的相對獲利能力,與資本設備(capital)業務相比如何?

  • Marshall Mohr - CFO

    Marshall Mohr - CFO

  • Yes, so first, talking about the range of I&A revenue per procedure, we would hope that we would be able to add to that number through increases in the advanced instrumentation, including stabling and vessel sealing. As I said, that's been somewhat muted or offset by the effects of foreign exchange over the last few quarters but there are other factors that could change that. I don't know what the historical high you are speaking about was, but I do think that there is room for it to grow going forward.

    好的,先談 I&A 每例手術營收的區間,我們希望能透過先進器械的增加來提升這個數字,包括吻合與血管封合。如我所說,過去幾個季度這部分在某種程度上受到外匯影響而被壓抑或抵銷,但也還有其他可能改變它的因素。我不確定你所指的歷史高點是多少,但我確實認為未來仍有成長空間。

  • Bob Hopkins - Analyst

    Bob Hopkins - Analyst

  • It was about $2,000, I think.

    我想大約是 2,000 美元。

  • Gary Guthart - President & CEO

    Gary Guthart - President & CEO

  • Remember that number has in it stocking orders and some timing of other things. So longer term, as you have a bigger and bigger install base, the relative value of stocking orders is going to go down and that has nothing to do with the pure economics of the exchange. The other question was around recurring revenue and remember, it's not just instruments; it is also service.

    請記得,那個數字包含備貨訂單(stocking orders)以及其他事項的一些時點因素。所以長期來看,隨著裝機基礎越來越大,備貨訂單的相對占比會下降,而這與外匯的純經濟性無關。另一個問題是關於經常性收入,請記得,不只是器械;也包括服務。

  • Marshall Mohr - CFO

    Marshall Mohr - CFO

  • It's about 50% instruments and accessories of revenue and 20% would be the service element to get to the 70% total recurring.

    約有 50% 的營收來自器械與配件,另外約 20% 會是服務項目,合計達到 70% 的經常性收入。

  • Calvin Darling - Senior Director of Finance and IR

    Calvin Darling - Senior Director of Finance and IR

  • And the margins on instruments and accessories are better than systems. So as we get a quarter where we have a higher mix of systems than the margins are going to be lower.

    而器械與配件的毛利率優於系統。因此,當某一季系統的組合占比較高時,毛利率就會較低。

  • Gary Guthart - President & CEO

    Gary Guthart - President & CEO

  • That trend is likely to be durable with I&A and service will be higher margin systems.

    這個趨勢很可能會持續,因為器械與配件以及服務的毛利率會高於系統。

  • Bob Hopkins - Analyst

    Bob Hopkins - Analyst

  • Great. Thank you very much.

    很好。非常感謝。

  • Operator

    Operator

  • Brandon Henry with RBC Capital Markets.

    RBC Capital Markets 的 Brandon Henry。

  • Brandon Henry - Analyst

    Brandon Henry - Analyst

  • Thanks for taking my question. So Intuitive has now shown two years of strong US urology growth. Can you discuss the reason for this outperformance in urology and how sustainable you think this strong performance is in 2016?

    謝謝讓我提問。Intuitive 現在已經展現連續兩年美國泌尿科的強勁成長。能否談談泌尿科表現優於預期的原因,以及您認為 2016 年這樣的強勢表現有多可持續?

  • Gary Guthart - President & CEO

    Gary Guthart - President & CEO

  • Brandon, thanks for the question. A year ago, you saw a turnaround in the volumes of da Vinci prostatectomy in the US, midpoint of the year and the back half of the year started to see some growth and that sustained throughout 2015. And the rate of growth has been certainly above what we believe the incidence rates of prostate cancer to be in the country.

    Brandon,謝謝你的問題。一年前,你看到美國達文西前列腺切除術的手術量在年中出現反轉,下半年開始看到一些成長,並且在 2015 年持續。而其成長率確實高於我們認為該國前列腺癌發生率的水準。

  • Also within US urology is growth in partial nephrectomy, as well, which has been pretty consistent and sustained, given the profile of what da Vinci technology brings to that procedure from both the clinical outcomes and cost-effectiveness perspective. As we look at 2016, our baseline assumption is that the high levels of growth that we've seen over the last six quarters are likely to begin returning more towards the incidence rates for the disease.

    此外,美國泌尿科內部分腎切除術也在成長,而且相當一致並具延續性,考量達文西技術在該手術於臨床結果與成本效益面所帶來的特性。展望 2016 年,我們的基準假設是,過去六個季度所見的高成長水準,可能會開始回歸到更接近該疾病的發生率。

  • Brandon Henry - Analyst

    Brandon Henry - Analyst

  • Okay and then one quick question on SP. Can you talk about why you decided to develop SP as essentially an add-on to the Xi Platform and not as its own stand-alone platform? And then maybe also talk about your expectations for SP instrumentation at launch. Do you anticipate having a Vessel Sealer and Stapler at launch that will work with SP? Thanks.

    好的,接著一個關於 SP 的快速問題。能否談談為什麼你們決定把 SP 開發成基本上是 Xi 平台的加掛(add-on),而不是獨立的單一平台?另外也請談談你們對 SP 在上市時的器械配置的預期。你們是否預期在上市時就會有可與 SP 搭配使用的血管封合器(Vessel Sealer)與釘合器(Stapler)?謝謝。

  • Gary Guthart - President & CEO

    Gary Guthart - President & CEO

  • On the reason to make it compatible with Xi, I think is really a straightforward thing, which is a lot of the components are shared in terms of certain console and Imaging Systems. We want the customer experience to be seamless for our customers. We think there are surgeons who go back and forth between SPs and Xi and what that means is that you want the user experience to be common.

    關於讓它與 Xi 相容的原因,我認為其實很直接,因為在某些控制台與影像系統等方面,許多元件是共用的。我們希望客戶的使用體驗能夠無縫銜接。我們認為有些外科醫師會在 SP 與 Xi 之間來回使用,這代表你會希望使用者體驗是一致的。

  • And we also make it easier for hospital departments to acquire capital. If they already have a dual console or Xi and they want to just add the SP card capability that makes the capital hurdle for them lower and so it strengthens the Xi ecosystem and I think that is a good idea and it's well received. So that has -- made sense for us. We haven't yet announced what our instrument kit will be for SP and when we get to the point, we will let you know.

    同時也讓醫院部門更容易取得資本設備。如果他們已經有雙控制台或 Xi,而只想再加上 SP 卡的功能,那麼他們面臨的資本門檻就更低,因此也強化了 Xi 的生態系;我認為這是個好主意,而且反應良好。所以這對我們而言——是合理的。我們尚未公布 SP 的器械套件會是什麼;等到時機成熟,我們會告訴各位。

  • Brandon Henry - Analyst

    Brandon Henry - Analyst

  • Okay. Thank you.

    好的。謝謝。

  • Operator

    Operator

  • Richard Newitter with Leerink Partners.

    Leerink Partners 的 Richard Newitter。

  • Richard Newitter - Analyst

    Richard Newitter - Analyst

  • Hi. Thanks for taking the questions. Maybe just one on SP and then I had one on the rotating bed. On SP, Gary, did you say that you are moving into clinical testing or some limited launch by the end of this year? Does that mean that's your official launch at the end of 2016? And --

    嗨。謝謝讓我提問。我先問一個關於 SP,然後再問一個關於旋轉手術床。關於 SP,Gary,你是否說你們會在今年底前進入臨床測試或某種有限度的上市?這是否表示你們在 2016 年底正式上市?然後——

  • Gary Guthart - President & CEO

    Gary Guthart - President & CEO

  • We don't expect material revenues in 2016. We are planning on clinical experiences in 2016.

    我們不預期 2016 年會有顯著的營收貢獻。我們計畫在 2016 年進行臨床使用經驗的累積。

  • Richard Newitter - Analyst

    Richard Newitter - Analyst

  • Okay, got it. And then on SP, on the approval process, I know you said that it's in discussion with the FDA right now. There is a competitor of yours that has a device that they are saying that they think they can get approval for their device based on larger buckets, or broader definitions of categories like urological procedures or general abdominal procedures.

    好的,了解。另外關於 SP 的核准流程,我知道你說目前正在與 FDA 討論。你們有一家競爭對手有一個裝置,他們表示他們認為可以用較大的「桶」(buckets),或更廣泛的類別定義(例如泌尿科手術或一般腹部手術)來取得核准。

  • Can you help us understand if this is something that you have heard the FDA say to you as well, or is it more nuanced than that and you need to go much more specific by individual procedures?

    你能否協助我們理解:這是否也是你們聽到 FDA 對你們這麼說的內容?還是其實更為細緻,你們需要針對個別手術做得更具體?

  • Gary Guthart - President & CEO

    Gary Guthart - President & CEO

  • The issue of broad claim language versus narrower claim language is actually was part of a discussion at the FDA workshop, and I can refer you to there those minutes, and you'll see pretty much what the exchange has been. The issue -- I would not view that as something that is architecture dependent or only offered to a certain company. That has to do -- in other words, FDA is going to respond to these kind of products in like manner as far as I can tell.

    關於廣泛的宣稱用語(claim language)與較狹窄的宣稱用語之間的議題,其實是 FDA 工作坊討論的一部分;我可以請你參考那份會議紀錄,你會看到整體的交流內容大致是什麼。這個議題——我不會把它視為取決於架構,或只提供給某一家公司的東西。換句話說,就我所知,FDA 對這類產品的回應方式會是一致的。

  • And so that comes down to FDA asked for a certain amount of data based on the kinds of things you want to talk to your customer about. And if you just want to talk about broad things and not specific things, then they asked for one set of data. And the more specific you get, the more data they asked for around that set of specifics. So, in general, it is a matching of data requirements with claims, and so they are describing to you a strategy around what they think they can do from a data requirement point of view. I think the playing field will be level here and to the extent the customers need a certain amount of information, then it's just going to be for all of us to go create that data and deliver it.

    因此,這取決於 FDA 會依據你想對客戶溝通的內容,要求一定程度的數據。如果你只想談較廣泛的內容而非特定事項,他們會要求一套數據。而你越具體,他們就會針對那一組具體事項要求更多數據。所以整體而言,就是把數據要求與宣稱相匹配;他們是在描述一個策略,說明他們認為從數據要求的角度可以做到什麼。我認為這裡的競爭環境會是公平的;而在客戶需要一定程度資訊的情況下,我們所有人都必須去產生那些數據並加以提供。

  • Richard Newitter - Analyst

    Richard Newitter - Analyst

  • Got it and just lastly on the bed. Can you help us understand what procedures, if any, or certain types of surgeons that might have been on the sidelines for whom this product might push them over the fence and really drive adoption on procedures that otherwise might have been slower to adopt? Are there any other specific procedures that could really open up? Thanks.

    了解,最後一個關於手術床的問題。你能否協助我們理解:有哪些手術(如果有的話)或哪些類型的外科醫師,可能原本還在觀望,而這個產品會讓他們下定決心,進而推動原本採用較慢的手術導入?是否還有其他特定手術可能因此真正被打開?謝謝。

  • Gary Guthart - President & CEO

    Gary Guthart - President & CEO

  • General surgeons routinely use that motion to do two things. To use gravity as a retractor, so it's an extra hand using gravity. And for the anesthesiologist to manage the patient in terms of positioning with regard to other vital signs and things like that.

    一般外科醫師經常使用那種移動來做兩件事。利用重力作為牽開器(retractor),也就是用重力當作一隻額外的手。以及讓麻醉科醫師能就病人的擺位來進行管理,並顧及其他生命徵象等事項。

  • So in procedures where you are trying to manage bowel, for example, it's really helpful to have table motion and that is clearly something that jumps out. However, once we've had it, we've now been CE Marked in Europe and we've had it trialed in different specialties, I think it appeal is broad. So we thought about it upfront initially around general surgery. I think its appeal will be broader than that.

    因此,在例如你需要處理腸道的手術中,手術台的移動功能非常有幫助,這點很明顯。不過,在我們已經擁有它之後,我們現在已在歐洲取得 CE 認證,也在不同專科進行試用,我認為它的吸引力是廣泛的。所以我們一開始確實是以一般外科來思考。但我認為它的吸引力會比那更廣。

  • Richard Newitter - Analyst

    Richard Newitter - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Rick Wise with Stifel Nicolaus.

    Stifel Nicolaus 的 Rick Wise。

  • Gary Guthart - President & CEO

    Gary Guthart - President & CEO

  • Rick, you will be our last questioner. You made it under the wire.

    Rick,你將是我們最後一位提問者。你趕在截止前進來了。

  • Rick Wise - Analyst

    Rick Wise - Analyst

  • Okay, thank you. (multiple speakers) I appreciate it, Gary. The -- maybe just to start with you, Gary. You said several times in the course of your prepared remarks and in the Q&A that robotics is in its infancy. Just a big picture for a second.

    好的,謝謝。(多位發言者) 謝謝你,Gary。那個——也許先從你開始,Gary。你在事先準備的發言以及問答中多次提到,機器人技術仍處於起步階段。先從宏觀角度談一下。

  • For you -- are you emphasizing it because perhaps this next wave of pipeline products that you talked about and maybe some you haven't talked about are getting you more confident or excited about the potential for another growth reacceleration or inflection point in the adoption of robotic surgery? Just -- I appreciate the numbers of systems placed relative to hospitals are small but just wondered if there was anything more there?

    對你而言——你之所以強調這點,是不是因為你提到的下一波產品管線,還有一些你可能尚未談到的產品,讓你對機器人手術採用率可能再度加速成長或出現拐點更有信心或更興奮?只是——我理解相對於醫院數量,系統裝機數仍然不多,但想知道是否還有更多含意?

  • Gary Guthart - President & CEO

    Gary Guthart - President & CEO

  • Sure, I think a couple things that excite me and lead me to believe there is a lot of opportunity. A couple. Well, one of them is that I think in the architectures we are in today are pitted in the markets for which we have clearances, there is still a lot of procedures that are being done open and have opportunity to be done minimally invasively with our products. And I think that is -- comes down to execution and delivery of some of the things we have in the pipeline.

    當然,我想有幾件事讓我感到興奮,也讓我相信仍有很大的機會。幾點。其中之一是,我認為以我們目前的架構、在已取得許可的市場中,仍有大量手術是以開放式進行,而有機會透過我們的產品以微創方式完成。而我認為這——歸根結底取決於我們在產品管線中一些事項的執行與交付。

  • Having said that, I think that as you just stand back and look out over the next decade and ask, do we think that robotic-assisted surgery can impact more procedures or more types of procedures than they are being impacted today, I think the answer to that is absolutely yes. Some things are things like SP, products that look different. SP won't be the last set of products that look different.

    話雖如此,我認為如果你退一步、放眼未來十年並問:我們是否認為機器人輔助手術能影響比今天更多的手術,或更多種類的手術?我認為答案絕對是肯定的。有些例子像是 SP,外觀不同的產品。SP 不會是最後一套外觀不同的產品。

  • We think there are opportunities for other products and technologies that can really make a difference in surgeons delivering great care. So we are excited about it. We're investing in it and I think ask just about any surgeon, do you think that the use of computation analytics and robotics is going to improve your practice over time or become less important. I think the answer is pretty uniform that those kinds of technologies should help them if they're well delivered and well executed.

    我們認為還有其他產品與技術的機會,能真正協助外科醫師提供優質照護。所以我們對此感到興奮。我們正在投入資源,我想你問幾乎任何一位外科醫師:你是否認為運算分析與機器人技術的使用,會隨時間推移改善你的臨床實務,還是會變得不那麼重要?我想答案相當一致:如果這些技術能被良好交付並妥善執行,確實應該能幫助他們。

  • Rick Wise - Analyst

    Rick Wise - Analyst

  • Got you. Two last quick ones I'll ask at the same time. Instrument and accessories growth, I think for the first time in at least five quarters, maybe longer, certainly since 2012 annually, grew -- did grow faster than procedures.

    了解。最後兩個簡短問題,我會一起問。器械與配件的成長,我想至少在五個季度以來、甚至更久,當然若以年度來看自 2012 年以來,第一次出現——其成長確實快於手術量。

  • Is there something that we should read into that with implications for the next couple years. Or is it just stock-in given the flattish revenues per procedure? And the second one, I'll throw at you at the same time. The bed approval, you launched in Europe in 2015. Just maybe -- did your early experience there -- did it drive utilization or procedures or Xi or capital sales? Any color there would be welcome.

    這是否有什麼我們應該解讀的訊號,對未來一兩年的含意是什麼?還是只是因為每例手術收入相對持平下的備貨(stock-in)?第二個問題我也一起問。床位核准(bed approval),你們在 2015 年於歐洲推出。想請問——你們在那邊的早期經驗——是否帶動了使用率或手術量,或 Xi 或資本設備銷售?任何補充說明都很歡迎。

  • Thanks, appreciate it.

    謝謝,感謝。

  • Marshall Mohr - CFO

    Marshall Mohr - CFO

  • On the revenue per procedure, I don't think there's much more than what we said. There's a lot of factors that impact that particular metric. It has been running at a pretty tight range, $1,830 to $1,840. It did take over to a growth this last quarter as we saw utilization of advanced instruments more than offset the headwinds mostly from exchange. But again, there a lot of those factors could vary in the future in terms of procedure mix, customer efficiency, buying pattern, foreign exchange. So it is really a lot of factors there.

    關於每例手術收入,我不認為還有超出我們所說的內容。有很多因素會影響這個特定指標。它一直維持在相當窄的區間,1,830 到 1,840 美元。上一季確實轉為成長,因為高階器械的使用增加,足以抵消主要來自匯率的逆風。但再次強調,未來這些因素仍可能變動,包括手術組合、客戶效率、採購模式、外匯。所以確實有很多因素在其中。

  • Gary Guthart - President & CEO

    Gary Guthart - President & CEO

  • On Xi, the certain feedback has been outstanding. Too soon to tell in terms of number of sites and duration as to what the changes and trends are. But we will be watching.

    關於 Xi,回饋確實非常出色。但就站點數量與時間長度而言,現在判斷變化與趨勢仍為時過早。不過我們會持續觀察。

  • Thanks Rick. That was our last question. As we've said previously, while we focus on financial metrics such as revenues, profits and cash flow during the conference call, our organizational focus remains on increasing value by enabling surgeons to improve surgical outcomes and reduce surgical trauma.

    謝謝你,Rick。那是我們最後一個問題。如同我們先前所說,雖然我們在電話會議中聚焦於營收、獲利與現金流等財務指標,但我們組織的重點仍是透過協助外科醫師改善手術結果並降低手術創傷,以提升價值。

  • I hope the following comments from Dr. Solomon, a general surgeon from Orlando, Florida, gives you some sense of the impact our products have on surgery. Quote, the Advanced Technologies and improved dexterity of the da Vinci Xi System have allowed me to perform complex minimally invasive operations with a statistically measurable improvement in outcomes. My patients are clearly and reproducibly benefiting from less pain, a shorter length of hospital stay, less time off work and lower short and long-term complications, end quote.

    我希望以下來自佛羅里達州奧蘭多的普通外科醫師 Solomon 醫師的評論,能讓各位感受到我們產品對手術的影響。引述:da Vinci Xi 系統的先進技術與更佳的靈活度,使我能執行複雜的微創手術,且在結果上有統計上可衡量的改善。我的病患明顯且可重複地受益於較少疼痛、更短的住院天數、更少的請假時間,以及較低的短期與長期併發症。引述結束。

  • We have built our Company to take surgery beyond the limits of the human hand and I assure you that we remain committed to driving the vital few things that truly make a difference. This concludes today's call. Thank you for your participation and we look forward to talking to you again in three months.

    我們打造公司,是為了讓手術超越人手的極限;我向各位保證,我們仍致力於推動那些真正能帶來改變的關鍵少數事項。今天的電話會議到此結束。感謝各位的參與,我們期待三個月後再與各位交流。

  • Operator

    Operator

  • Ladies and gentlemen, that does conclude your conference for today. Thank you for your participation and for using the AT&T Executive Teleconference Service. You may now disconnect.

    各位女士、先生,今天的電話會議至此結束。感謝各位的參與,以及使用 AT&T 高階主管電話會議服務。您現在可以掛線。